Koch M, De Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams ALL, Kranendonk MEG, Van Scheltinga AGTT, Aichler M, Jansen L, De Vries J, Lub-De Hooge MN, Schroder CP, Jorritsma-Smit A, Linssen MD, De Boer E, Van Der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van Der Wall E, Garcia-Allende PB, Van Diest PJ, De Vries EGE, Walch A, Van Dam GM, Ntziachristos V (2017)
Publication Type: Conference contribution
Publication year: 2017
Publisher: SPIE
Book Volume: 10411
Conference Proceedings Title: Progress in Biomedical Optics and Imaging - Proceedings of SPIE
Event location: Munich, DEU
ISBN: 9781510612808
DOI: 10.1117/12.2286062
In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
APA:
Koch, M., De Jong, J.S., Glatz, J., Symvoulidis, P., Lamberts, L.E., Adams, A.L.L.,... Ntziachristos, V. (2017). Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. In J. Quincy Brown, Ton G. van Leeuwen (Eds.), Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Munich, DEU: SPIE.
MLA:
Koch, Maximilian, et al. "Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold." Proceedings of the Clinical and Preclinical Optical Diagnostics 2017, Munich, DEU Ed. J. Quincy Brown, Ton G. van Leeuwen, SPIE, 2017.
BibTeX: Download